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ABSTRACT
DIFFERENTIAL ENDOMETRIAL RESPONSES OF 
PRIMATES VS RODENTS: SCREENING FOR 
ANTIPROLIFERATIVE EFFECTS OF ANTIPROGESTINS
David Williams Burleigh 
Eastern Virginia Medical School 
and
Old Dominion University, 1997 
Director D r Gary D. Hodgen
The antiprogestin, mifepristone, has previously been shown to noncompetitively 
inhibit estrogen-induced endometrial proliferation in nonhuman primates (van Uem et al., 
1989; Wolf et al., 1989b; Neulen et al., 1990; Neulen et al., 1996). For both economical 
and ethical reasons, we are encouraged to identify comparative laboratory rodent models 
which can substitute the need to use primate models. In the following study, we compared 
capabilities of the rat uterine weight bioassay versus a primate uterine bioassay, to identify 
the noncompetitive antiestrogenic/antiproliferative effects of mifepristone.
Long-term ovariectomized monkeys were exposed to exogenous l7|3-estradiol 
(E2) and mifepristone in doses and regimes already demonstrated to curtail endometrial 
growth (Wolf et al., 1989b). Results show that mifepristone decreased endometrial 
proliferation in a dose-dependent manner, and this decrease occurred in the presence of 
physiologic serum E2 levels.
In the rat model, ovariectomized immature (day 20) and adult Sprague-Dawley 
rats were pretreated with E2 for 3 days, followed by E2 plus mifepristone (various doses) 
for 3 additional days. E2 replacement was either given as 0.5 pg/100 g body weight (in oil, 
sc) or as a 0.5 mg sc pellet. Mifepristone did not induce a decrease in uterine wet or 
blotted weights in immature or adult rats receiving E2 replacement as 0.5 pg/100 g body 
weight (P>0.05). This lack of effect was not due to insufficient E2 stimulation as 
histological evaluation of the endometrium showed increased numbers of mitotic figures in 
all treatment groups and serum E2 levels were in the diestrous-proestrous range. In 
contrast, mifepristone did inhibit an increase in uterine wet weight of adult rats (P<0.05)
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and immature rats (P<0.01) receiving E2 replacement as O.S mg E2 pellet. Uterine blotted 
weights were also effected by treatment with mifepristone in the immature rats (P<0.05). 
Serum E2 levels attained in rats given the O.S mg E2 pellet were pharmacological (>800 
pg/ml), illustrating a relationship between E2 levels and capability of mifepristone to affect 
rat uterine weight.
Based on the results summarized here, we do not recommend using the rat uterine 
weight bioassay as a substitute model for screening antiprogestins for noncompetitive 
antiestrogenic/antiproliferative effects on primate uterine endometrium.
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The drug RU38486 (17p-hydroxy-l 1 p-(4-dimethyIaminophenyl)-17a-( 1 - 
propynyl)-estra-4, 9-dien-3-one; Roussel-Uclaf), also called mifepristone, was developed 
in 1980 as a potential antiglucocorticoid. Because previous company data showed some 
binding cross-reactivity between the glucocorticoid receptor (GR) and the progesterone 
receptor (PR), Roussel-Uclaf conducted receptor binding tests to identify possible 
receptor cross-reactivity. The receptor binding tests revealed that mifepristone, in addition 
to recognizing the glucocorticoid receptor, showed significant binding affinity for the 
progesterone receptor; and to a much lesser extent, the androgen receptor (Baulieu,
1989). This cross-reactivity is not surprising as subsequent work has shown a 90% amino 
acid sequence identity in the GR and PR DNA-binding regions and a 55% amino acid 
sequence identity in the COOH-terminal region (Evans, 1988).
As the capability of a synthetic steroid compound to bind a steroid receptor can 
not accurately predict its in vivo agonistic or antagonistic effects (Baulieu, 1989), studies 
evaluating the antiprogestational effects of RU486 were necessary. The secretion of 
progesterone by the corpus luteum is well known to be necessary for the maintenance of 
pregnancy in women (Csapo et al., 1972; Jones, 1976), as luteectomy followed by 
progesterone replacement therapy prevents pregnancy loss (Csapo et al., 1973). Philibert 
and others (1982) evaluated the use of mifepristone to block progesterone action and 
induce termination of pregnancy in rats. Building from the success of these experiments, 
the capability of mifepristone to block progesterone action and induce abortion in women 
was also investigated. Principally due to mifepristone’s capability to induce early 
pregnancy termination in women, the steroid quickly became labeled by anti-abortion 
groups as the abortion-pill.
The following dissertation text style is modeled after Molecular Reproduction and 
Development.
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Multiple uses for mifepristone have been proposed and identified, including, ovulation 
inhibition (Danforth et al., 1989; Wolf et al., 1989a), treatment for breast cancer 
(McDonnell and Goldman, 1994), pregnancy termination (Ulmann, 1987; Ji, 1988), 
contragestation (Glasier et aL, 1992; Webb et al., 1992),
treatment of leiomyomas (Murphy et al., 1993), treatment of progesterone receptor 
containing meningiomas (Grunberg, 1994), and treatment of endometriosis (Kettel et al, 
1991; Grow et al., 1996; Kettel et al., 1996). Yet, it is the highly controversial abortive 
properties of the drug that have garnered so much attention of the press and public and 
made RU486 recognized.
Generalized Description of Gene Transcription
Figure 1A diagrams a very simplified representation of a steroid-inducible 
eukaryotic gene. In general, the transcription of mRNA from such a gene requires RNA 
polymerase II and accessory proteins which recognize the promoter sequence. These 
accessory proteins are termed transcription factors, which are proteins needed for the 
initiation of transcription but are not themselves a component of RNA polymerase Q. The 
promoter is a region of DNA that contains binding sites for the transcription factors. Most 
eukaryotic promoters contain the consensus sequence TATA approximately 25 base pairs 
upstream of the transcription start site. In addition, the gene sequence contains a hormone 
response element (HRE). The HRE is a DNA binding site that induces transcription when 
activated by its respective Iigand-receptor complex, and prevents transcription in the 
nonactivated state; thereby regulating hormone-induced transcription. Steroid receptors 
are proteins that can be viewed as ligand-dependent transcription factors (Kraus et al.,
1995). It is generally accepted that unliganded steroid receptors reside within the nucleus 
and are believed to be loosely associated with DNA (Mester and Baulieu, 1995; Catt,
1996). Following activation by a ligand, the receptors undergo tight DNA binding to the 
hormone response element (HRE) and initiate gene activation.
Figure IB illustrates a possible model for activation of an estrogen-inducible gene. 
Upon entering the cell, estrogen binds to its receptor (ER) and promotes tight association 
of the Iigand-receptor complex to the estrogen response element (ERE). Binding of the
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activated estrogen-receptor complex to the ERE initiates formation of the transcription 
complex and the binding of RNA polymerase II. It is thought that binding of the estrogen- 
receptor complex to the ERE likely induces a change in the three dimensional structure of 
the gene, bringing the transcription complex into close physical contact with the estrogen- 
receptor complex (Nardulli et al., 1993). Interaction between these two elements activates 
RNA polymerase II and initiates mRNA transcription. Translation of the mRNA leads to 






|— Promoter region —}








Fig. I. Conceptualized view of steroid-inducible gene activation. (A) Illustrates binding regions for the 
promoter complex and hormone receptor complex. (B) Binding of the activated estrogen receptor complex 
to the ERE induces a 3-D change in the gene and brings the promoter complex into close physical contact 
with the receptor, initiating mRNA transcription. Model adapted from Kraus and others (1995).
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Cell Cycle
The progression of a cell through the cell cycle, is in part, regulated by the activity 
of a special class of protein kinases called cyclin-dependent kinases. In turn, activation of 
the cyclin-dependent kinases are positively regulated by association with a catalytic 
subunit called cyclin. Numerous cyclins have been identified and classified according to 
their conserved amino acid sequence motifs, and apparent function (Geum et al., 1997). 
Cyclin-dependent kinase Dl has been identified in steroid regulation of cell growth and 
appears to be necessary for progesterone-dependent mammary development, as cyclin Dl- 
deficient mice do not develop lobular mammary alveoli during pregnancy (Musgrove et 
ai., 1997). Cyclin-dependent inhibitor, p21, is known to inhibit cyclin-dependent kinase 
activity. In the G( phase of the cell cycle (Figure 2), D-type cyclins are involved in 
activating the powerful growth-inhibitory protein retinoblastoma tumor suppresser protein 
(pRB). When pRB is hypophosphorylated it actively blocks cell mitosis by sequestering 
transcription factors. Cyclin-dependent kinase Dl is involved in the hyperphosphoryiation 
of pRB, which then releases the transcription factors and allows the progression of cell 
mitotis (Weinberg, 1996).
Musgrove and others (1997) have recently presented data describing mifepristone- 
induced cell cycle inhibition in T-47D breast cancer cells. T-47D cells are progesterone 
responsive cancer cells and are frequently used by investigators to study the in vitro 
effects of progestins. In these experiments a 3- to 4-fold increase in p21 levels was 
observed in the cells 12-24h after treatment with mifepristone. The increase in p21 levels 
was associated with a decrease in cyclin-D 1 kinase activity and an increase in the ratio of 
hypophosphorylated pRB.hyperphosphorylated pRB.
These data would strongly indicate that mitotic arrest of T-47D cells (and possibly 
other types of progesterone responsive cells) by mifepristone is due to an upregulation of 
p21, decreased activity of cyclin-D 1 kinase, and inactivation of pRB. These actions most 
likely occur during Gi phase, at which point in time proteins required for mitosis are 
synthesized. This would suggest that the lack of necessary cell-division proteins acts to 
direct cells into a long-term, or permanent, Go phase (Cameron et aL, 1996).








replication restriction point where cell
commits to mitosis
Fig. 2. Stages of the cell cycle. Mifepristone-induced inhibition of cell mitosis may occur during the Gi 
phase by altering the synthesis and activity of cell-division proteins. Model adapted from Weinberg
( 1996).
Repression of Estrogen-Induced In Vitro Transcription by Mifepristone
Four models describing the repression of transcription have been proposed by 
Levine and Manley (1989) and Kraus and others (1995), these being, direct repression, 
competitive repression, squelching, and quenching. In direct repression a repressor protein 
binds to the DNA at a site distant to the promoter region and sterically interferes with 
formation of the transcription complex. Competitive repression occurs when the repressor 
protein binds to a DNA site overlapping or shared by the transcription complex, and 
prevents its ability to bind to the DNA. In comparison, squelching is observed when the 
over expression of a transcription factor sequesters other needed factors and prevents 
them from forming the transcription complex. Lastly, quenching occurs when a repressor 
and activator bind distinct DNA sites, yet interaction between the two prevents the 
activator from making proper contact with the transcription complex.
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McDonnell and Goldman (1994) have proposed that mifepristone induces 
antiestrogenic activities through the progesterone receptor A isoform; and not B isoform. 
In their studies, monkey kidney CV-I fibroblasts were transiently transfected with a mouse 
mammary tumor virus-estrogen response element-luciferase reporter. The transfected cells 
also included expression vectors for human progesterone receptor A or B (PRA and 
PRB), and an expression vector for hER. Results showed that luciferase activity was 
decreased to approximately 60% of control levels in cells transfected with the PRA. This 
decrease in luciferase activity was completely absent in cells transfected with the PRB; 
indicating a partial estrogen receptor antagonism in cells coexpressing PRA. These authors 
favored the mechanism of squelching to describe the noncompetitive inhibition of hER by 
hPRA.
In a similar set of experiments by Kraus and others (1995), rat uterine cells were 
transiently transfected with Rous sarcoma virus promoter-driven rat estrogen receptor 
vector (pRSV-rER), pRSV-human progesterone receptor A (-hPRA), pRSV-hPRB, 
hormone response elements ERE and PRE, and a chloramphenicol acetyltransferase 
reporter gene. Results from these experiments showed that cells treated with mifepristone 
had an approximately 85% decrease in CAT activity, regardless of which hPR isoform 
they contained. These data would indicate that in rat uterine cells, both PRA or PRB can 
act as an inhibitor of ER-mediated transcriptional activity. These authors supported the 
model of quenching to explain their data on transcriptional repression of the ER by 
activated PR.
Antiestrogenic Effects of Mifepristone in Primate Endometrium
Mifepristone was first reported to inhibit estrogen-induced endometrial 
proliferation in the non-human primate by van (Jem and others (1989). van Uem and 
others measured a decreased endometrial thickness in intact monkeys treated with 
mifepristone. As mifepristone has been reported to not bind the ER (Moguilewsky and 
Philibert, 1985), these authors concluded that the antiestrogenic effect of the antiprogestin 
was very likely the result of noncompetitive actions. This experiment by van Uem and 
others was quickly followed by an additional study from Wolf and others (1989b), who
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showed that mifepristone induced a decrease in endometrial thickness and reduced the 
mitotic index in the endometrium of ovariectomized estrogen-supplemented monkeys. The 
paradoxical noncompetitive antiestrogenic effect of mifepristone in nonhuman primates 
has been supported by Slayden and Brenner (1994). These authors found that mifepristone 
decreased uterine wet weight and increased amount of DNA per mg uterine tissue (DNA 
M-g/mg tissue wet weight). Surprisingly, these antiestrogenic effects were only noted in the 
endometrium and not the oviduct, thus showing tissue selectivity.
The mitogenic capacities of estrogen on uterine tissue are well known. As estrogen 
induces transcription of cyclin-D 1 kinase mRNA during mouse uterine cell proliferation 
(Geum et al., 1997), it is possible that cyclin-Dl, p21, or pRB proteins are effected during 
the inhibition of estrogen-induced endometrial proliferation by mifepristone in nonhuman 
primates. The atrophic appearance of mifepristone-treated nonhuman primate 
endometrium is not due to decreased estrogen receptor concentration (Neulen et al., 1990; 
Slayden and Brenner, 1994; Neulen et al., 1996).
Purpose
Since the late 1930s it has been established that the proestrus surge of estrogen in 
rats stimulates uterine fluid retention (Astwood, 1939). Release of this uterine fluid is 
accomplished by actions of progesterone in relaxing the cervix and allowing it to escape 
via the vagina (Armstrong, 1968). Building upon this known effect of estrogen, the 
standard accepted animal model assay used to assess the estrogenic or antiestrogenic 
capability of new compounds is the m vivo immature rat uterine weight assay (Kirkland et 
aL, 1979). In this assay, ovariectomized rats are given estradiol replacement to stimulate 
water retention and endometrial proliferation. A positive estrogenic response can be 
determined by an increase in uterine wet weight and uterine blotted weight, respectively. 
The simultaneous administration of estradiol and an antiestrogenic compound should both 
decrease water retention and uterine blotted weight, in comparison to the estradiol-treated 
control. In regards to estrogen controlled growth, no model has been proven to be more 
effective than the rat uterine bioassay. Accordingly, here we have compared the rodent 
model with a primate model for evaluation of antiproliferative actions of mifepristone.
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Our laboratory has a continuing interest in examining the antiestrogenic effects of 
mifepristone and other antiprogestins. The use of antiprogestins may be beneficial in 
controlling breakthrough bleeding during progestin-only contraception (Williams et aL,
1997) and treatment of endometriosis (Grow et al., 1996; Kettel et al., 1996). While 
evaluating the antiestrogenic effects of mifepristone using the rat uterine weight bioassay, 
results from our preliminary experiments indicated that the bioassay might fail to identify 
certain compounds capable of suppressing endometrial proliferation in nonhuman 
primates, and as such, may not be suited for conventional high-throughput screening of 
compounds. High throughput screening can be loosely defined as the testing of a large 
number of compounds for detection of a limited number of specific endpoints. Based upon 
whether these endpoints are observed, each compound is then accepted or eliminated from 
further testing. Validity of this testing procedure is dependent on the chosen endpoints 
truly reflecting the compounds’ desired capability. The negative results in our preliminary 
studies are indirectly supported by two earlier studies. An acute study by Okulicz (1987) 
indicated that ovariectomized rats retained E2-induced uterine fluid during treatment with 
mifepristone. In addition, Szabo and others (1996) reported that proestrus rats given 
mifepristone showed uterine imbibition [uterine ballooning]. Both of these studies 
suggested that administration of mifepristone would not affect the estrogen-induced 
accumulation in uterine fluid. As these two studies and our preliminary rat experiments 
failed to show noncompetitive antiestrogenic/antiproliferative effects of mifepristone, we 
chose to replicate the study of Kraus and Katzenellenbogen (1993) which reported 
antiproliferative effects of mifepristone in immature rats. Replication of this study was 
necessary to show that differences their and our study were due to experimental methods 
(i.e., method of E2 replacement). In addition, we conducted an experiment using 
cynomolgus monkeys to reassert that mifepristone does cause antiproliferative effects on 
primate endometrium. Therefore, the goal of this study was to determine if a difference 
exists between the rat uterine weight bioassay and a nonhuman primate uterine assay in 
their capability to identify antiestrogenic effects of mifepristone. Those interested in the 
screening of antiprogestin candidate compounds may benefit from our experiences and 
observations reported herein.




17P-estradiol and progesterone were purchased from Sigma Chemical Comp., (St. 
Louis, MO). l7p-estradiol pellets were purchased from Innovative Research of America 
(Cat. #E121, Sarasota, FL). The mifepristone used in these experiments was purchased 
from China and its bioavailability and potency are equivalent to RU486.
Animals and Treatments
All Sprague Dawley rats used in these experiments were purchased from Harlan 
Sprague Dawley, Inc. (Indianapolis, IN). The animals were maintained in a temperature 
controlled room (24-27°C) under a 14h-10h, light-dark cycle, and given food and water 
ad libitum. In the experiments using adult animals, females were ovariectomized when 
approximately 250 g of weight and allowed a minimum of 10 days to recover before 
starting hormone treatment. In experiments using immature animals, females were 
ovariectomized on day 16 of age and allowed to recover for 4 days before starting 
hormone treatment. The animals were randomly assigned to a treatment group following 
ovariectomy (5 per group). Hormone treatments for animals of both ages were given for 6 
days, 3 days of 17P-estradiol pretreatment (either l7f3-estradiol in oil or as a pellet), 
followed by 3 days of 17P-estradiol plus mifepristone. 17p-estradiol was given as a daily 
single sc injection (0.5 pg/100 g body weight (BW), in com oil) or as a single sc 0.5 mg 
pellet implant. Mifepristone was dissolved in com oil and administered as a daily single sc 
injection at the doses indicated in figures or tables. Vehicle control animals received the 
appropriate volume of com oil. Cardiac blood samples were collected under ketamine- 
rompun induced anesthesia from a group of similarly treated animals on days 1, 3, 5, and 7 
for determination of estradiol levels.
Fifteen long-term ovariectomized cynomolgus monkeys (Macaca fascicularis), 
weighing approximately 2-4 kg, were maintained in a temperature controlled room (22°C) 
with a I2h light-dark cycle, and given food and water ad libitum. The animals were
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assigned to one of five treatment groups (3 per group), as follows: 1, vehicle control, 3 cm 
placebo containing silastic capsule, implanted sc, plus, daily sc injections of com oil; 2, 
l7P-estradiol (E2) control, 3 cm estradiol containing silastic capsule (-150 mg E2), 
implanted sc, plus, daily sc injection of com oil; 3, E2 capsule plus mifepristone (0.01 
mg/kg/day, sc, in oil); 4, E2 capsule plus mifepristone (0.1 mg/kg/day, sc, in oil); 5, E2 
capsule plus mifepristone (1.0 mg/kg/day, sc, in oil). The estradiol capsule was implanted 
on day 1 and left in place for 21 days. Starting on day 1, animals were treated with vehicle 
or mifepristone for 20 days. Femoral blood samples (3.5 cc) were collected under 
ketamine-induced anesthesia on days 1, 5, 9, 13, 17, and 21 for determination of estradiol 
levels.
Uterine Tissue Collection and Histology
One hour prior to tissue collection, all rats received a 0.1 ml sc injection of com oil 
containing 5 |ig E2 and 2 mg progesterone to activate the steroid receptors and induce 
nuclear translocation (Kraus and Katzenellenbogen, 1993). Rats were euthanized by C02 
asphyxiation and the entire reproductive tract removed as one piece from the cervix to the 
distal ends of the uterine homs. The tissue was stripped of fat and quickly weighed to 
obtain the uterine wet weight, distal ends of the uterine homs were cut and the fluid gently 
expelled, and the tissue was weighed again to obtain the uterine blotted weight. After 
weighing, the uterine tissue was placed into 10% buffered formalin and processed for 
hemotoxylin and eosin (H&E) staining.
Histology was performed on two cross-sections from each rat. Each cross-section 
was morphologically examined for the number of mitotic figures in the endometrium and 
glands. Mitotic activity was determined by counting the number of cells showing 
metaphase chromosomes or a condensed nucleus with clear cytoplasm. Each cross-section 
was also examined for the number of cells showing nuclear fragmentation.
Uterine biopsies were obtained from each monkey on day 21 of the experiment.
Full thickness endometrial biopsies were placed in 10% buffered formalin and processed 
for H&E staining. Histological analysis of the endometrium was performed on a single 
section by the criteria of Noyes and others (1950). Each section was morphologically
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examined for the number of mitotic figures in the endometrium, glands, and stroma. 
Mitotic activity was determined by counting the number of cells showing metaphase 
chromosomes or a condensed nucleus with clear cytoplasm. Mean endometrial thickness 
for each animal was obtained by averaging at least four separate determinations using 
Image-Pro Plus software (Media Cybernetics, Silver Spring, MD) on a Olympus BX50 
microscope.
Radioimmunoassay
Monkey serum levels of 173-estradiol were measured by radioimmunoassay (RIA) 
using a commercially available kit from ICN Biomedicals, Inc., (Costa Mesa, CA), and 
quality control standards of known potency from BioRad (Hercules, CA). All serum 
samples were measured in a single assay. The intraassay coefficient of variance for the 
BioRad control of similar potency as the unknowns was 9%. Our labs historical interassay 
coefficient of variance for this assay is <10%. The assay sensitivity for 173-estradiol was 
10 pg/ml.
Rat serum levels of 173-estradiol were measured by Covance Laboratories Inc., 
(Vienna, VA), using an in-house assay with rabbit antiserum, HWA E2. Cross-reactivity 
of this antiserum is 8.48% for 173-dihydroequilenin and negligible for all other tested 
steroids. The reported intraassay coefficient of variance and interassay coefficient of 
variance from Covance are 10.76% and 12% respectively. The assay sensitivity for 173- 
estradiol was 10 pg/ml.
Preliminary Rat Experiments and Post-Ovariectomy Recovery Period
In our initial experiments (estrogen dose response curve and Preliminary 
Experiments 1-4), adult Sprague Dawley rats, were purchased, cared for, and treated by 
identical conditions as previously described; with the following exceptions. Both the 
estrogen dose response experiment and Preliminary Experiment I used adult rats that had 
a post ovariectomy recovery period of >4 days. The method of E2 replacement and/or 
length of E2 treatment changed between experiments and is described with the associated 
Figure and Tables.
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In the rat experiments presented herein, it is acknowledged that the post­
ovariectomy recovery period, was a variable we did not totally control. Two experiments 
with adult rats used a 4 day recovery period (approximately 1 estrous cycle). The recovery 
period was increased to 10 days (2 estrous cycles) in all subsequent adult studies to 
facilitate the clearance of all circulating ovarian steroids and to allow uterine atrophy prior 
to experiment initiation. In the Latin Square design experiments that repeated a published 
treatment regime (Kraus and Katzenellenbogen, 1993), we maintained our established 10 
day surgery recovery period for adult rats, but observed the 4 day recovery period for 
immature rats used by these authors.
For the following reasons, it is our belief that this variable did not play a role in 
determining experimental outcome: 1) Immature rats were ovariectomized at 16 days of 
age prior to the initiation of significant endogenous ovarian steroid production; 2) Serum 
E2 levels were barely detectable in adult rats sampled 10 days after surgery; and 3)
Vehicle control tissue in all experiments consistently showed the lack of exposure to E2.
In addition, it is acknowledged that the length of time from ovariectomy to 
initiation of an experimental treatment is not consistent between monkeys and rats. Long­
term ovariectomized monkeys (versus short-term) were used in these experiments for 
reasons of availability, because steroid hormone levels were barely detectable, and because 
maximal uterine atrophy had been established.
Statistical Analysis
Number of mitotic cells, cells showing nuclear fragmentation, uterine wet weight, 
and uterine blotted weight, were statistically compared by analysis of variance using Instat 
GraphPAD Software, version l.l la (1990). Significant differences between group means 
were determined by Fisher’s least significant difference test, with values being considered 
significant at P<0.05.
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Ethical Treatment of Animals
All animals were housed in facilities approved by the American Association for the 
Accreditation of Laboratory Animal Care. These studies were approved by the Animal 
Care and Use Committee of Eastern Virginia Medical School and carried out according to 
NTH guidelines and USD A regulations.




As expected, mifepristone was highly proficient in the inhibition of estrogen-driven 
mitogenesis of primate endometrial tissue. These data confirm our prior published results 
(van Uem et al., 1989; Wolf et aL, 1989b; Neulen et aL, 1990). All animals used in this 
study were long-term ovariectomized (> 9 months). In order to stimulate growth of the 
endometrium, monkeys received estrogen replacement therapy given as a 3 cm E2 
containing silastic capsule, sc, for 21 days. The mean serum E2 levels attained in each 
treatment group are shown in Figure 3. All treatment groups receiving an E2 capsule 
maintained serum E2 levels in the physiological range. The higher serum E2 values in the 
0.1 mg/kg mifepristone group were likely due to random variation in implant steroid 
releasing kinetics.





Fig. 3. Serum estradiol levels in monkeys given a 3 cm E2-containing silastic capsule and treated with 
mifepristone. All points represent the mean + SEM of three determinations, except for E2 control (day 1) 
and 1.0 mg mifepristone (day 21) which represent two determinations + range. All treatment groups given 
the E2 capsule maintained a physiological level of E2 throughout the experiment






























Vehicle 0.92 ±0.1* small rounded 0/10 0/10 atrophic
E2 control 2.83 ± 0.3b dilated tubular 19/10 0.3/10 mid proliferative
E2 plus mifepristone 2.11 ±0.2b tubular 10/10 0,3/10 mid proliferative
(0.01 mg/kg)
E2 plus mifepristone 1.6410.1* small rounded 3/10 0/10 weak proliferative
(0.1 mg/kg)
E2 plus mifepristone 0.67 ±0.1* small rounded 1.7/10 0/10 very weak
(1.0 mg/kg) proliferative
Animals were treated with either a 3 cm E2-containing silastic implant or a vehicle-containing implant for 21 days. Daily injections of mifepristone (at doses 
indicated) began on day I and were continued for an additional 19 days. Uterine biopsies were obtained on day 21.
1 Glandular mitotic activity = average number of mitotic cells/10 glands.
2 Stromal mitotic activity = average number of mitotic cells/10 fields @ 400X,
Means with different superscripts are significantly different (P<0,0S),
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Antiestrogenic Effects of Mifepristone on Monkey Endometrium
Histological results showing the effect of mifepristone on monkey endometrium 
are illustrated in Table I and Figure 4. In the vehicle control group, the lack of ovarian 
steroids was associated with endometrium showing very densely positioned nuclei in the 
stroma and being completely void of glandular and stromal mitotic activity (Fig. 4A). With 
the addition of E2 to the experimental model (E2 control group), a marked induction of 
endometrial growth was observed. The endometrial classification for this group of 
monkeys was mid-proliferative, as shown by appearance of dilated tubular-shaped glands, 
stromal edema, and presence of glandular mitotic activity (Fig. 4B). The mean endometrial 
thickness in the E2 control group was significantly different from the vehicle control group 
(P<0.01). In relationship to the E2 control group, treatment with E2 plus 0.01 mg/kg 
mifepristone did not inhibit E2-induced endometrial growth (P>0.05) nor affect general 
endometrium morphology (Fig. 4C). Increasing the dose of mifepristone to 0.1 mg/kg, 
reduced the level of glandular mitotic activity, produced an endometrium with small 
rounded glands, and further reduced the endometrial thickness (Fig. 4D). The endometrial 
thickness of the 0.1 mg/kg mifepristone group was not different from either the vehicle 
control or E2 control groups (P>0.05), indicating the appearance of antiestrogenic effects. 
Animals treated with 1.0 mg/kg mifepristone showed a further reduction in glandular 
mitotic activity and a compact stromal morphology closely resembling that in the vehicle 
control group. As shown in Figure 4E the glands were few, small and rounded. The 
endometrial thickness attained in the 1.0 mg/kg mifepristone group was not different from 
the vehicle control group (P>0.05), and was different from the E2 control group 
(P0.001). Histological classification of the 1.0 mg/kg mifepristone group was weak 
proliferative and not atrophic, as in the vehicle control group. This difference in 
classification indicates that mifepristone can suppress growth of the endometrium to a 
level equal to the vehicle control, yet at the same time does not completely inhibit all 
estrogenic activity.
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Fig. 4. Comparison o f endometrial appearance from cynomolgus monkeys treated with E2 plus 
mifepristone. Paraffin embedded tissue was sectioned at 5pm, stained with H&E and photographed at 
(X40). Tissue from the vehicle control group (panel A) shows a dense, compact stromal cell density with 
no observable edema. In contrast, tissue from the E2 control group (panel B) is characterized by increased 
endometrial thickness, elongated dilated glands, and stromal edema. (*) Approximate border o f the 
endometrium and myometrium.
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F ig . 4. (continued). Photographs of monkey endometrial tissue. Tissue from the E2 + 0.01 
mg/kg mifepristone treatment group (panel C) shows tubular glandular morphology and stromal edema. 
Endometrium thickness in this group did not differ from the E2 control group (P>0.05). Panel D shows 
endometrial tissue from the E2 + 0.1 mg/kg mifepristone treatment group, tissue from this group was 
characterized by small round glands, decreased stromal edema, and decreased endometrial thickness. 
Endometrial thickness of this group did not differ from the vehicle control group or E2 control group 
(P>0.05). (*) Approximate border of the endometrium and myometrium.
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Fig. 4. (continued). Photograph shows endometrial tissue from the E2 + 1.0 mg/kg mifepristone 
treatment group (panel E). The endometrium in this group was marked by an almost complete lack of 
glands stromal compaction, and an endometrial thickness not different from the vehicle control group 
(P>0.05). (*) Approximate border of the endometrium and myometrium.
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Rat Preliminary Experiments
A series of experiments using the rodent model were conducted to determine 
optimal doses of E2 and mifepristone required to affect uterine imbibition and uterine 
blotted weight. As our overall study design included establishment of a rodent model to 
replace the primate uterine model, our initial studies used adult rats as a comparative 
physiological model for adult monkeys.
Figure 5 illustrates the increase in uterine wet weight in response to various doses 
of E2. The ideal E2 dose desired would be a value approximating the midpoint of the 
uterine response curve. As shown in Figure 5, the E2 dose most closely meeting this 
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Fig. 5. Estrogen dose response curve. Ovariectomized adult rats were treated once daily for 3 days with 
various doses of E2 (in oil, sc). Uterine wet weight values were determined on the morning o f day 4. 
Animals In this experiment were ovariectomized £4 days prior to steroid treatment

















TABLE 2. Preliminary Experiment 1. Uterine Weights of Ovariectomized Adult Rats1 Treated for 3 Days
with 6pg E2/100 g BW plus Mifepristone.
wet weight (g) blotted weight (g)
Treatment mean ± SEM mean ± SEM
Vehicle control 0.307 ±0.015* 0.293 ±0.014*
E2 control 1.627 ± 0.13 lb 0.547 ±0.014b
E2 + 0.005 mg mifepristone 1.597 ±0.144b 0.565 ± 0.021b
E2 + 0.05 mg mifepristone 1.646 ±0.196 b 0.588 ±0,068 b
E2 + 0.5 mg mifepristone 1.206±0.138b 0.548 ±0,031b
'Rats were given a £4 day post-ovariectomy recovery period before starting steroid treatment. 

















TABLE 3. Preliminary Experiment 2. Uterine Weights of Ovariectomized Adult Rats1 Treated for 3 Days
with 6|ig E2/100 g BW plus Mifepristone.
Treatment
wet weight (g) blotted weight (g)
mean ± SEM mean ± SEM
Vehicle control 0.216 ± 0.007* 0.211 ±0.007*
E2 control 1.340 ± 0.171b 0.497 ± 0.034 b
E2 + 0.5 mg mifepristone 1.535 ±0.184b 0.486 ± 0.028 b
E2 + 1,5 mg mifepristone 1.121 ±0.108b 0.460 ± 0.01 l b
E2 + 5.0 mg mifepristone 1.203 ±0.155b 0.459 ±0.015 b
'Rats were given a £10 day post-ovariectomy recovery period before starting steroid treatment. 
Treatment means with a different superscript are significantly different (P<0,05).
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Previous studies already mentioned that used the monkey model had indicated that 
mifepristone inhibited endometrial proliferation. In an effort to maintain a similar 
mifepristone dose (mg/kg) in the rat model, we began these studies examining the effect of 
0.005 mg, 0.05 mg, and 0.5 mg mifepristone, total dose per animal (doses approximate 
0.015 mg/kg, 0.15 mg/kg, and 1.5 mg/kg). In addition, the rat uterine weight bioassay 
conventionally uses a 3 day steroid treatment period and we followed this accepted 
protocol.
Data from Preliminary Experiment 1 did not identify antiestrogenic effects of 
mifepristone in adult rats, as determined by a decrease in uterine imbibition or uterine 
blotted weight (P>0.05, Table 2). Consequently, in our following experiment we chose to 
increase the mifepristone total dose per animal to 0.5 mg, 1.5 mg, and 5.0 mg. Data from 
this experiment (Preliminary Experiment 2) show that even these high levels of 
antiprogestin did not inhibit the increase in uterine wet and blotted weights induced by 6 
Mg E2/100 g BW (P>0.05, Table 3). Concern was expressed that the dose of 6 pg E2/100 
g BW may establish serum E2 levels exceeding the physiologic range, and therefore, 
possibly over-ride the noncompetitive antiestrogenic effects of mifepristone. The dose 0.5 
Mg E2/100 g BW was selected from the literature (L’Horset et al., 1993) as sufficient to 
mimic E2 peak levels during proestrus. Uterine weights of adult rats treated with 0.5 pg 
E2/100 g BW and mifepristone are shown in Table 4 (Preliminary Experiment 3). These 
data show that all treatment groups receiving mifepristone were not significantly different 
from the E2 control group (P>0.05).
It had been reported that ovariectomized rats not pretreated with E2 failed to 
respond to progestin treatment (Kraus and Katzenellenbogen, 1993; L’Horset et al.,
1993). The lack of response is thought to be due to decreased expression of PR. As our 
previous three experiments failed to identify antiestrogenic effects of mifepristone in the 
ovariectomized rat, it was possible that the lack of response was due to very low uterine 
PR expression. To determine if E2 pretreatment was necessary in our rodent model, we 
treated rats with 0.5 pg E2/100 g BW for 3 days, followed by the same dose of E2 plus 
mifepristone for 3 consecutive days (Preliminary Experiment 4). Mifepristone did not 
demonstrate any antiestrogenic affects under these conditions. Thus, results of this
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experiment show that E2 pretreatment did not affect the capacity of mifepristone to cause 
antiestrogenic effects in adult rats (P>0.05, Table 5).
Kraus and Katzenellenbogen (1993) have reported antiestrogenic effects of 
mifepristone in ovariectomized immature rats as determined by a decrease in uterine 
imbibition. Since the methodology used by these authors differed considerably from our 
own, we believed it necessary to conduct a comparative study. A Latin Square 2x2 study 
was designed to test adult rats versus immature rats given E2 replacement as either 0.5 pg 
E2/100 g BW or 0.5 mg E2 pellet.
Although the treatment regime modeled after that described by Kraus and 
Katzenellenbogen (1993), i.e., Preliminary Experiment 4, did not identify noncompetitive 
antiestrogenic effects of mifepristone, we empirically chose to continue this treatment 
regime. The variable, post-ovariectomy recovery period, was held at 10 days for adult rats 
to facilitate ovarian steroid clearance and uterine atrophy. To replicate the experiment 
described by Kraus and Katzenellenbogen (1993), we were obligated to observe the 4 day 
surgery recovery period for immature rats. In addition, we continued to use the E2 dose of 
0.5 pg E2/100 g BW to maintain E2 stimulation within the physiologic range.

















TABLE 4. Preliminary Experiment 3. Uterine Weights of Ovariectomized Adult Rats1 Treated for 3 Days
with Physiologic Levels of E2 Replacement (0.5 pg E2/100 g BW) plus Mifepristone.
Treatment
wet weight (g) blotted weight (g)
mean ± SEM mean ± SEM
Vehicle control 0.204 ±0.018* 0.201 ±0.017*
E2 control 1.179 ± 0.073b 0.442 ± 0.039 b
E2 + 0.1 mg mifepristone 1.080 ±0.144b 0.445 ± 0.029 b
E2 + 0.5 mg mifepristone 1.203 ±0.170b 0.452 ± 0.032 b
E2 + 1.5 mg mifepristone 1.114±0.110b 0.466 ± 0.032 b
E2 + 5.0 mg mifepristone 1.192 ± 0.096 b 0.484 ± 0.032b
'Rats were given a £10 day post-ovariectomy recovery period before starting steroid treatment. 


















TABLE S. Preliminary Experiment 4. Effect of E2 Pretreatment on Uterine Weights of Ovariectomized
Adult Rats1 Treated for 3 Days with 0.5 pg E2/100 g BW plus Mifepristone.
Treatment
wet weight (g) blotted weight
mean ± SEM mean ± SEM
Vehicle control 0.195 ± 0,004' 0.192 ± 0.003'
E2 control 0.841 ±0.216' 0.518 ± 0.031b
E2 + 0.1 mg mifepristone 1.088 ±0.252' 0.531 ± 0.040b
E2 + 0.5 mg mifepristone 1.006 ±0,188' 0.484 ± 0.023b
E2 + 1.5 mg mifepristone 0.881 ±0.179* 0.493 ±0.012b
E2 + 5.0 mg mifepristone 1.168 ±0.109* 0.517 ±0.014b
Animals were pretreated with E2 at O.S pg E2/100 g BW alone for 3 days, followed by an additional 3 days of E2 plus mifepristone 
or E2 alone. Treatment groups with a different superscript are significantly different (P<0.03).




In order to establish the approximate serum E2 levels attained by the two different 
E2 delivery methods, we treated a representative group of animals and collected cardiac 
blood samples on days 1 (pretreatment control), 3, 5, and 7. The mean serum E2 values 
are shown in Figure 6. Administration of 0.5 pg E2/100 g BW to both immature and adult 
rats maintained daily average serum E2 levels in the range of 10-35 pg/ml. These values 
correspond to physiologic levels attained in diestrus and proestrus. In comparison, animals 
given the 0.5 mg E2 pellet attained extraordinary supraphysiologic serum levels of E2. 
These values ranged from 80- to 600-fold greater than the levels reached by treatment 
with 0.5 pg E2/100 g BW. The higher E2 levels measured in the immature rats versus 








'Adult, 0.5 ug/lOOg BW
'Immature, 0.5 mg
-Immature, 0.5 ug/lOOg 
BW
Days of treatment
Fig. 6. Seram estradiol levels in adult and immature rats. Animals were either implanted on day 1 with a 
0.5 mg E2 pellet, sc, or treated daily with 0.5 tig E2/100 g BW for 6 days. Serum samples were collected 
by cardiac puncture on the days indicated. Animals receiving the 0.5 mg pellet attained E2 levels 80- to 
600-fold greater than animals given 0.5 \ig E2/100 g BW. All points represent the mean + SEM of three 
determinations, except immature day 1 (control) which represents mean + range of two determinations.
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Antiestrogenic Effects of Mifepristone on the Estradiol-Primed Rat Uterus
In contrast to the monkey data, the rat uteri did not manifest the capacity of 
mifepristone to curtail endometrial growth, even at doses 16-fold greater (mg/kg) than 
that used in the monkey. Interestingly, mifepristone did appear to impair water retention in 
certain experiments, even while the rat uterine weight bioassay proved inappropriate for 
the demonstration of the antiproliferative actions of this antiprogestin.
F ig . 7. Effect of 0.5 (ig E2/100 g body weight on adult rat uterine tissue. (A) Control tissue, (B) E2 
treated tissue. Note uterine ballooning and increased tissue growth induced by the treatment with
estrogen.
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In the first experiment, the antiestrogenic effect of mifepristone was assessed in 
adult animals treated with 0.5 pg E2/100 g BW/day. The uteri of animals from the vehicle 
control group were small, flaccid, and contained a negligible weight of fluid (Fig. 7 A). In 
contrast, the uteri of animals from the E2 control group were large and turgid (Fig. 7B). 
The E2 control group had a mean fluid volume of 0.3 ml and showed a 3 .6-fold increase in 
wet weight and a ~2-fold increase in blotted weight compared to that observed in the 
vehicle control group. These results clearly illustrate that this amount of E2 does have 
stimulatoty effects on rat uterine tissue.
The uterine wet and blotted weights of adult rats treated with 0.5 pg E2/100 g BW 
are shown in Figure 8. In this experiment, uterine weights of all treatment groups 
receiving mifepristone did not differ from their respective E2 control (P>0.05; Fig. 8A and 
B).
Similar results were obtained in the second experiment which assessed the 
antiestrogenic effects of mifepristone in immature animals treated with 0.5 pg E2/100 g 
BW/day. In this experiment, uteri of animals from the E2 control group showed a 4-fold 
increase in both uterine wet weight (P<0.05; Fig. 9A) and blotted weight (P<0.05; Fig.
9B) in comparison to the vehicle control group. As in the adult rat experiment, the 
immature rat uterine wet and blotted weights from all mifepristone-treated groups did not 
differ from their respective E2 control group (P>0.05). Taken together, data from these 
two experiments indicate that mifepristone does not affect the change in uterine wet 
weight or uterine blotted weight induced by 0.5 pg E2/100 g BW.
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Fig. 8. Uterine weight values attained in adult rats given 0.5 pg E2/100 g BW/day and treated with 
mifepristone. Treatment groups are: vehicle control (V); estradiol control (E2); E2 + 0.1 mg mifepristone; 
E2 + 0.5 mg mifepristone; E2 +■ 1.5 mg mifepristone; and E2 + 5.0 mg mifepristone. Each column 
represents the mean + SEM for five determinations. Columns with a  different superscript are significantly 
different (P<0.05). Uterine wet and blotted weights in the mifepristone treated groups were not 
significantly different from their respective E2 control group. Columns without bars indicate that the SEM 
is within the column.
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Fig. 9. Uterine weight values attained in immature rats given 0.5 pg E2/I00 g BW/day and treated with 
mifepristone. Treatment groups are: vehicle control (V); estradiol control (E2); E2 + 0.1 mg mifepristone; 
E2 + 0.5 mg mifepristone; E2 + 1.5 mg mifepristone; and E2 + 5.0 mg mifepristone. Each column 
represents the mean + SEM for five determinations. Columns with a different superscript are significantly 
different (P<0.05). Animals treated with mifepristone did not show a decrease in uterine wet or blotted 
weights in comparison to their respective E2 control group. Columns without bars indicate that the SEM 
is within the column.
R eproduced with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
Previous work by Kraus and Katzenellenbogen (1993) reported antiestrogenic 
effects of 1.5 mg mifepristone in immature rats treated with a 0.5 mg E2 pellet. As our 
previous experiments failed to detect any antiestrogenic effect of mifepristone in rats 
treated with 0.5 pg E2/100 g BW, we were interested in comparing our experimental 
model to that of Kraus and Katzenellenbogen.
In this experiment adult animals treated with a 0.5 mg E2 pellet showed a 
tremendous increase in uterine wet weight (2.21 g) in comparison to the vehicle control 
(0.2 g). This increase in uterine wet weight was inhibited by treatment with mifepristone at 
all doses (P<0.05; Fig. 10A), with there being no statistically significant difference 
between the lowest and highest dose groups. The uterine blotted weight of the 0.1 mg 
mifepristone and 0.5 mg mifepristone groups were different from the E2 control group 
(P<0.05; Fig. 10B), however, this significance was marginal since the alpha probability 
was between 0.04 and 0.05. Blotted uterine weights of the 1.5 mg and 5.0 mg 
mifepristone groups were not significantly different from the E2 control (P>0.05).
When immature animals were treated with the 0.5 mg E2 pellet, an ~ 15-fold 
increase in uterine wet weight and 5-fold increase in uterine blotted weight were observed 
in comparison to the vehicle control, (0.62 g vs 0.04 g) and (0.2 g vs 0.04 g) respectively. 
Similar to that shown in the adult animals, all doses of mifepristone were able to inhibit the 
E2-induced increase in uterine wet weight (P<0.01; Fig. 11A). In addition, mifepristone 
decreased uterine blotted weight by approximately 15% in all treatment groups (P<0.05; 
Fig. 1 IB). These data are in agreement with Kraus and Katzenellenbogen (1993), who 
reported a 17% decrease in uterine wet weight of animals treated with 0.5 mg E2 pellet 
and 1.5 mg mifepristone.
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Fig. 10. Uterine weights attained in adult rats given a  0.5 mg E2 pellet and treated with mifepristone. 
Treatment groups are: vehicle control (V); estradiol control (E2); E2 + 0.1 mg mifepristone; E2 + 0.5 mg 
mifepristone; E2 + 1.5 mg mifepristone; and E2 + 5.0 mg mifepristone. Each column represents the mean 
+ SEM for five determinations. Columns with a  different superscript are significantly different (P<0.05). 
E2 control animals showed a  dramatic increase in uterine wet weight This increase was effectively 
inhibited by treatment with mifepristone at all four doses. Columns without bars indicate that the SEM is 
within the column. *Note change in scale.
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F ig . 11. Uterine weight attained in  immature rats given a  0.5 mg E2 pellet and treated with 
mifepristone. Treatment groups are: vehicle control (V); estradiol control (E2); E2 + 0.1 mg mifepristone: 
E2 + 0.5 mg mifepristone; E2 + 1.5 mg mifepristone; and E2 + 5.0 mg mifepristone. Each column 
represents the mean + SEM for five determinations. Columns with a  different superscript are significantly 
different (P<0.05). The E2 treated group showed a 15-fold increase in uterine weight in comparison to the 
vehicle control group. This estrogen-induced weight increase was inhibited by treatment with 
mifepristone. Columns without bars indicate that the SEM is within the column.
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Histological Analysis
To help understand the effect of mifepristone on rat endometrial morphology, uteri 
from the four rat experiments were stained with H&E and histologically examined for 
number of mitotic figures and cells with nuclear fragmentation. A comparison of these 
parameters are shown in Tables 6 and 7. These data show that within each experiment, the 
number of mitotic cells and cells with a fragmented nucleus in the E2 control group were 
not significantly different from the mifepristone-treated groups (PX).05). As such, the 
difference in uterine blotted weight observed in those experiments using the 0.5 mg E2 
pellet is not due to a mifepristone-induced decrease in mitotic activity or increase in cell 
death. It is interesting to note that in animals given 0.5 jig E2/100 g BW/day, the number 
of mitotic cells and cells showing nuclear fragmentation were greater in relationship to 
their age-matched counter parts given a 0.5 mg E2 pellet.

























E2 + 0.1 mg 
mifepristone
E2 + 0.5 mg 
mifepristone
E2 + 1.5 mg 
mifepristone




2 ± 1 44 ±8 38 ±4 34 ±7 36 ±4 36 ± 5
Adult rats 
0.5 mg E2 pellet
2 ±0.5 6 ± 1 9 ± 1,5 8 ± 1 9± 1 7 ± 1
Immature rats 
0,5 pgE2/100g
0.2 ± 1 18 ± 5 15 ±4 14 ±2 17 ± 3 26 ±5
Immature rats 
0.5 mg E2 pellet
0±0 3 ±0.5 4 ±0.5 3 ±0.4 3 ±0.5 4 ± 1
Animals were pretrcated with E2 at (0,5 pg/lOOg BW) or (0.5 mg pellet) alone for 3 days, followed by an additional 3 days of E2 plus mifepristone or E2 
alone. Mifepristone treated groups were not significantly different from their respective E2 control group (P> 0,05).


















TABLE 7. Number of Cells with Nuclear Fragmentation1 (Mean ± SEM) Measured in Ovx, Adult and Immature Rats,







E2 + 0,1 mg 
mifepristone
E2 + 0.5 mg 
mifepristone
E2+ 1.5 mg 
mifepristone




0.1 ±0.1 13 ±9 21 ±15 31 ±21 27 ±8 45 ±35
Adult rats 
0.5 mg E2 pellet
0.2 ±0.2 1 ±0.5 3 ± 1 2 ± 1 1,5 ± 0.5 1.5 ±0.5
Immature rats 
0,5 pg E2/100 g
0±0 10 ± 3 8 ±4 4 ± 1 10 ± 3 11 ±3
Immature rats 
0.5 mg E2 pellet
0 ±0 0.5 ±0.4 0.5 ±0.3 0.4 ±0.2 0.5 ±0.3 0 ± 0
Animals were pretreated with E2 at (0.5 pg/100 g BW) or (0.5 mg pellet) alone for 3 days, followed by an additional 3 days of E2 plus mifepristone or E2 
alone. Mifepristone treated groups were not significantly different from their respective E2 control group (P> 0.05).




Before our laboratory’s initial reports in 1989, there was no appreciation of a class 
of antiprogestin compounds that conferred antiestrogenic/antiproliferative effects upon 
uterine tissue. Accordingly, in the absence of binding to the ER, antiestrogenic effects of 
mifepristone were simply not anticipated. Although the primate is an extremely useful 
animal model for comparative physiological studies in humans, considerable financial and 
ethical issues remain a constant companion when conducting primate research. As such, 
the application of other animal models to replace the primate is important.
The immature rat uterus is frequently used by corporate scientists as a target organ 
for high-throughput screening of estrogenic compounds. Two easily observable classic 
responses in the rat uterus to exogenous estrogen include increased cell proliferation and 
water retention. Utilization of the rat model greatly decreases the economical and ethical 
burdens surrounding the use of primates in research. Therefore, it is prudent for 
investigators to use this less controversial animal model when possible.
The experiments reported herein, have examined the ability of the rat uterine 
weight assay to detect previously established noncompetitive antiestrogenic effects of 
mifepristone on estrogen-induced endometrial proliferation. Our findings suggest that the 
rat uterine weight bioassay is not an appropriate laboratory model suitable for screening 
antiprogestins for medical indications in which women’s tissues grow in response to 
estrogen.
Results from our nonhuman primate experiment have clearly confirmed the 
noncompetitive antiestrogenic effect of mifepristone on endometrial proliferation. These 
data by themselves although not novel, do confirm the antiestrogenic nature of 
mifepristone and allow a direct comparison to the rat model. The present experiment and 
those of others (van Uem et al., 1989; Wolf et al., 1989b; Neulen et al., 1990; Slayden and 
Brenner, 1994) all show that mifepristone reliably inhibits E2-induced endometrial 
proliferation in ovariectomized monkeys in a dose dependent manner. Stromal compaction 
was not statistically evident in this study at the two lowest mifepristone doses (0.01 and 
0.1 mg/kg). However, the 0.1 mg/kg dose appeared to be a partially effective dose as the
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endometrial thickness did not differ from either the vehicle control or E2 control groups. 
The 1.0 mg/kg mifepristone dose did not induce development of an atrophic endometrium 
as shown in the vehicle control group. This limited ability of mifepristone to completely 
suppress estrogenic effects may increase its applicability to treat various diseases.
During this experiment, all monkeys were observed daily for the presence of 
menstrual bleeding. Throughout the entire 21 day study period, all animals remained 
amenorrheic (data not shown).
Our preliminary rat experiments that used adult animals and various treatment 
regimes did not identify noncompetitive antiestrogenic effects of mifepristone. As our 
nonhuman primate data clearly shows the noncompetitive antiestrogenic capacity of 
mifepristone, validity of the rat uterine weight assay was brought into question. To correct 
for the possible lack of, or paucity of progesterone receptor and ineffectiveness of 
mifepristone in the rat model, the total treatment time was lengthened to 6 days; 3 days of 
E2 pretreatment, and 3 days of E2 plus mifepristone treatment. Indeed, E2 pretreatment 
may be necessary to upregulate the progesterone receptor in ovariectomized rats before 
effects of progestins can be assessed (Katzenellenbogen, 1980; L’Horset et al., 1993).
The mean serum E2 levels in rats given 0.5 pg E2/100 g BW were in the normal 
physiologic range of diestrus and proestrus. In comparison, serum E2 levels established in 
rats given the 0.5 mg E2 pellet were pharmacologic. Animals treated with the E2 pellet 
maintained a daily mean serum E2 level ranging from 80- to over 600-fold greater than 
rats given 0.5 pg E2/100 g BW. These values are much higher than the 40 pg/ml average 
for the proestrus estradiol surge in rats (Smith et al., 1975). The lower level of serum E2 
established by 0.5 pg E2/100 g BW did not stimulate as dramatic an increase in uterine 
wet weight in the E2 control animals as did treatment with the 0.5 mg E2 pellet. In 
addition, rats given 0.5 pg E2/100 g BW did not show a decrease in uterine wet weight 
when treated with mifepristone. At this time the association between serum E2 levels and 
the capability of mifepristone to affect uterine wet weight is not felly understood.
It has been reported by Kraus and Katzenellenbogen (1993) that ovariectomized 
immature rats treated with a 0.5 mg E2 pellet show a down-regulation in uterine ER 
expression. After 2 days of treatment, uterine tissue from rats receiving the E2 pellet
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expressed only 15% of control ER levels, and this level remained steady throughout the 
remaining 6 day treatment period. Levels of uterine PR (B isoform) were also measured in 
these same animals. A 7-fold increase in PR levels was attained after 2 days of treatment 
and a 10-fold increase was attained by end of the 6 day treatment period. The regulation 
of steroid receptors in ovariectomized rats given various levels of E2-supplementation has 
also been reported by Manni and others (1981). These authors report that rats given from 
0 to 50 pg E2/day for 5 days show a dose-related decrease in total level of uterine 
estrogen receptors. Although uterine ER and PR expression were not measured in our 
experiments, it is likely our animals given the 0.5 mg E2 pellet would have shown a similar 
regulation of these steroid receptors. The possible increased number of ERs in our animals 
given 0.5 pg E2/100 g BW is supported by the observation of a greater number of mitotic 
cells in these animals; which is a classic estrogen-driven response. The increased mitotic 
index in these animals occurred despite having much lower serum E2 levels in comparison 
to animals given the 0.5 mg E2 pellet. These data would then suggest that the decreased 
numbers of mitotic cells observed in the E2 pellet-treated animals could be due to down- 
regulation of the ER. If these assumptions are valid, it appears that the decrease in uterine 
wet weight caused by mifepristone in our experiments required the presence of a low level 
of ER expression, a high level of PR expression, and a high serum E2 level. Slayden and 
Brenner (1994) have proposed that increased levels of PR expression is important for the 
ability of mifepristone to have antiestrogenic effects in the rhesus monkey. Up-regulation 
of the PR may provide a mechanism by which squelching or quenching of estrogen gene 
activity could occur. Therefore, it is possible that the ratio ofPR.ER coupled with high 
serum E2 levels are key factors that may regulate the ability of mifepristone to have 
antiestrogenic effects in the rat.
Mifepristone decreased the uterine blotted weight of rats in both experiments that 
used the 0.5 mg E2 pellet. Although statistically significant, the absolute weight 
differences between treatment groups within these two experiments is very small, and as 
such, emphasis should not be strongly placed upon the difference. When comparing age- 
matched rat experiments, it is evident that E2 replacement given as 0.5 pg /100 g BW 
versus 0.5 mg pellet, led to approximate equal uterine blotted weight values; yet at the
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same time, those animals treated with 0.5 pg E2/100 g BW had greatly increased numbers 
of mitotic cells and cells showing nuclear fragmentation. The disparity of these data 
indicate that the observed decrease in uterine wet weight in animals given a E2 pellet was 
more likely due to a decrease in uterine fluid retention, and not in addition, the apparent 
inhibition of cell growth. Kraus and Katzenellenbogen (1993) also observed a decrease in 
uterine wet weight in mifepristone treated rats. These authors interpreted their results as 
an indication of the ability of mifepristone to inhibit E2-induced increase in uterine growth; 
however, this assessment was made in the absence of histological evaluation. Although 
our data do indicate a difference in mitotic and fragmenting cell numbers between 
experiments, this activity was not associated with a change in uterine weight.
It has been proposed that mifepristone elicits its antiestrogenic effects via the PR A 
isoform (McDonnell and Goldman, 1994). The absence of observed antiestrogenic effects 
by mifepristone in these experiments is not due to the lack of PRA in the rat uterus, as 
Ilenchuk and Walters (1987) have measured a 3:1 ratio of PRAiPRB in rat uteri. Second, 
the only species identified to date that do not recognize mifepristone are the chicken, 
hamster, and tammar wallaby (Benhamou et al., 1992; Lim-Tio et al., 1996). Lastly, it has 
been reported that mifepristone does have antiprogestin effects in the rat, as shown by 
impairment of implantation and embryo development (Psychoyos and Prapas, 1987; 
Roblero and Croxatto, 1991), and pregnancy termination (Chang et al., 1993).
Other mechanisms have been proposed to describe the antiestrogenic effects of 
mifepristone. Two of these mechanisms include, inhibition via PRA and PRB (Kraus et al., 
1995), or by an over expression of the ER (Neulen et al., 1996). It is apparent that the 
observed inhibition is not due to a down-regulation of uterine ER, as both Slayden and 
Brenner (1994) and Neulen and others (1996) have measured an increased expression of 
ER in mifepristone treated animals. The mechanism(s) by which mifepristone induces its 
antiproliferative effects on the nonhuman primate endometrium remains unknown.
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CONCLUSIONS
In the absence of both physiological and pharmacological serum estradiol levels, 
failure of the rat uterine weight assay to confirm the nonhuman primate data indicating 
curtailment of endometrial proliferation, illustrates an extreme limitation and brings in to 
question the utility of using the rat uterine weight bioassay to screen lead antiprogestins 
compounds for potential noncompetitive antiestrogenic activity. Although we only 
analyzed the single antiprogestin mifepristone, it seems likely that other antiprogestins 
possess antiproliferative effects on primate endometrium. Our data indicate that the 
antimitogenic capability of these compounds would likely not be identified using the rat 
uterine weight bioassay. In summary, the rat uterine weight bioassay, in contrast to the 
primate uterine assay, is not a valid in vivo model for detecting, or for quantifying the 
noncompetitive antiestrogenic/antiproliferative effects of mifepristone.
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